Overview of Xusal

Quick Facts: Xusal (Levocetirizine)

Property	Description
Active ingredient	Levocetirizine dihydrochloride
Form	Film-coated tablets, Oral solution
Pharmacological class	Second-Generation Antihistamine
Common use	Relief of allergic discomfort
Origin	Synthetic, Chiral derivative

What Type of Medicine is Xusal?

Xusal is a medicinal product whose active component is levocetirizine dihydrochloride, and it is fundamentally classified as a second-generation antihistamine. This specific class of medication is designed to manage symptoms arising from the body's allergic response. Xusal belongs to the therapeutic group of specific histamine H1 receptor antagonists. This classification confirms that the medicine is primarily used to counteract the effects of histamine release. As a type of peripheral H1 receptor antagonist, it works systemically, targeting receptors mainly outside the brain. This design is widely clinically recognized for providing relief with a generally lower risk of the central nervous system effects associated with older compounds.

Xusal's Composition and Origin

The core composition of Xusal centers on the single-ingredient, synthetic compound levocetirizine. It is manufactured for the oral route of administration and is available as a film-coated tablet and an oral solution, with the solution being a key differentiating form often marketed for use in pediatric patients. Levocetirizine is unique because it is a chiral derivative and represents the active R-enantiomer of its progenitor drug, cetirizine. This refinement is critical to its identity: by containing only the pharmacologically active component, the formulation concentrates the desired therapeutic activity.

What is Xusal's General Therapeutic Purpose?

Xusal's general purpose is to provide foundational relief from the discomfort associated with common allergic responses, such as irritation caused by seasonal allergens. The medication achieves this by exerting its primary action as a selective H1 receptor blocker. By occupying these receptor sites, levocetirizine prevents the natural chemical histamine, which is released during an allergic reaction, from binding and initiating the cascade of symptoms. This targeted inhibition of allergic signaling helps to effectively control and reduce the general bodily overreaction to environmental allergens.

What side effects are possible with Xusal?

Possible Side Effects and Safety Information

The possible adverse reactions associated with Xusal (levocetirizine) are classified by frequency, which is determined from clinical trial data and post-marketing surveillance as documented by official regulatory authorities.

Documented Adverse Reactions

Classification	Common Reactions (1 to 10 in 100)	Uncommon Reactions (1 to 10 in 1,000)
System-Organ Class	Nervous System / Gastrointestinal	General / Gastrointestinal
Adverse Effect	Somnolence, fatigue, headache, dry mouth	Asthenia, abdominal pain

Serious Adverse Reactions and Safety Constraints

Adverse reactions documented through post-marketing experience are generally classified as Not Known frequency. These reports cover effects across several System-Organ Classes, including Immune System Disorders, Nervous System Disorders, Psychiatric Disorders, and Renal and Urinary Disorders.

Specific serious adverse reactions highlighted in regulatory labeling include anaphylaxis, convulsions, hallucinations, suicidal ideation, and urinary retention. Caution is advised for patients with existing predisposing factors for urinary retention, such as prostatic hyperplasia.

Safety constraints noted in official documents include a contraindication in end-stage renal disease (creatinine clearance less than 10 mL/min) and caution for older adults due to the higher likelihood of reduced renal function. Additionally, concurrent use with alcohol or other CNS depressants may result in additive reductions in mental alertness.

Overdose and Emergency Response

Taking more than the recommended dose of Xusal (levocetirizine) can lead to an overdose. The severity of overdose symptoms can vary depending on the amount taken and the individual's age.

Symptoms of Overdose

Symptoms in adults typically include drowsiness.

In children, overdose may initially manifest as agitation or restlessness, which can progress to drowsiness.

In rare but severe cases in both adults and children, an overdose of antihistamines like levocetirizine may involve:

Rapid heart rate (tachycardia)
Significant drowsiness or lethargy
Confusion or delirium
Seizures or convulsions

When to Seek Help

If you suspect that you or someone else has taken an overdose of Xusal, seek emergency medical assistance immediately.

Even if symptoms appear mild, it is critical to contact a poison control center or your local emergency services for professional guidance. Antihistamine overdoses can sometimes present with mild initial symptoms that may worsen over time. Treatment for an overdose is primarily supportive, focusing on managing symptoms and ensuring the medication is cleared from the body, and may require monitoring of vital signs in a healthcare setting.

To prevent accidental overdose, all medications, including Xusal, should be stored safely out of the reach of children.

Therapeutic Uses of Xusal

Main Uses of Xusal

Xusal, which contains the active substance levocetirizine, is an antihistamine medication used to manage symptoms associated with allergic conditions. It works by blocking the effects of histamine, a substance produced by the body during an allergic reaction.

Allergic Rhinitis

The primary use of this medication is for the relief of symptoms associated with allergic rhinitis. This includes both seasonal allergic rhinitis (commonly known as hay fever) and perennial allergic rhinitis, which occurs year-round. Symptoms typically addressed include:

Sneezing: Reducing the frequency and intensity of sneezing fits.
Rhinorrhea: Management of a runny or itchy nose.
Nasal Congestion: Helping to alleviate the feeling of a blocked nose.
Ocular Symptoms: Relieving itchy, red, or watery eyes often associated with pollen or pet dander allergies.

Chronic Urticaria

Xusal is also indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria. This condition is characterized by the chronic appearance of wheals (hives) and skin eruptions that occur without a known cause. The medication helps to:

Reduce Itching: Diminish the localized itching associated with hives.
Decrease Lesions: Reduce the number and severity of wheals on the skin.

Benefits of Treatment

The benefit of using Xusal lies in its ability to improve the quality of life for individuals suffering from persistent allergic symptoms. By mitigating the physical discomfort of rhinitis and urticaria, the medication helps to restore normal daily functioning and reduce the sleep disturbances often caused by nighttime allergy symptoms. As a later-generation antihistamine, it is designed to provide relief with a lower likelihood of causing drowsiness compared to first-generation antihistamines.

Regulatory References

NIH MedlinePlus Drug Information on Levocetirizine

Eligibility and Restrictions for Use

Xusal (levocetirizine) is generally indicated for the relief of symptoms associated with allergic rhinitis and chronic hives in adults and children aged 6 years and older. However, its use is contraindicated and should be avoided in specific patient groups due to the risk of serious side effects or drug accumulation.

Contraindications (Who Cannot Use Xusal)

Known Allergy: Individuals with a known hypersensitivity or allergic reaction to levocetirizine, cetirizine, hydroxyzine, or any of the ingredients in Xusal.
Severe Kidney Disease: Patients with end-stage renal disease or those undergoing hemodialysis (with a creatinine clearance rate typically less than 10 mL/min). Xusal is primarily eliminated by the kidneys, and severe impairment leads to drug accumulation.
Pediatric Kidney Impairment: Children aged 6 to 11 years with any degree of impaired renal function should not use this medication.

Precautions (Use with Caution)

Consult a healthcare provider before use if you have:

Urination Problems: Conditions that predispose you to urinary retention, such as an enlarged prostate or a spinal cord lesion, as Xusal may increase this risk.
Epilepsy or Risk of Seizures: Caution is advised as Xusal may, in rare cases, cause or worsen seizures.
Moderate to Severe Kidney Impairment (Ages 12+): Dose adjustment is required based on the severity of renal function to prevent accumulation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile of levocetirizine (Xusal) is structured by documented patterns involving additive effects with CNS depressants, specific changes to drug clearance, and procedural timing requirements.

Pharmacodynamic and Substance Interactions

Concurrent use with alcohol or other Central Nervous System (CNS) depressants (such as sedatives or tranquilizers) should be avoided. This is because official documents cite the potential for an additive impairment of CNS performance and an additional reduction in alertness.

Pharmacokinetic and Clearance Notes

Specific medicines are documented to alter the exposure of levocetirizine's active component. Ritonavir co-administration causes an increase in the plasma AUC (exposure) and half-life of cetirizine. Separate data indicates that Theophylline co-administration results in a measurable decrease in the clearance of cetirizine. Additionally, in vitro data suggests levocetirizine itself is unlikely to cause clinically relevant pharmacokinetic interactions by inhibiting or inducing CYP enzymes.

Restrictions and Constraints

The drug may be taken with or without food, as food intake only delays the rate of absorption but does not reduce the total extent absorbed. A 3-day wash-out period is required before a patient undergoes allergy skin testing because the medicine inhibits the necessary response. Use is formally contraindicated in patients with End-Stage Renal Disease (Creatinine Clearance <15 mL/min or on dialysis) due to its primary dependence on renal excretion.

Mechanism of Action

Targeted Receptor Blocking and Signal Interference

Xusal acts as a highly selective antagonist (blocker) on specific biological receptors, primarily within peripheral systems. This direct, targeted binding occupies the receptor site and prevents the body's natural signaling molecules from activating the receptors, thereby disrupting the initial signaling event that triggers a molecular cascade.

Modulation of Downstream Signaling Cascades

By interrupting the primary receptor activation, Xusal effectively dampens downstream signaling cascades. This action is relevant in biological systems where specific transmitters or mediators dominate, influencing the dynamics of overactive physiological responses. This targeted pathway adjustment restricts the magnitude of excessive mediator activity, resulting in reduced activation within the affected pathways.

Mechanism of Reduced Pathway Activity

The overall mechanistic effect of Xusal is to engage mechanisms that regulate dysregulated or overactive processes. The drug modifies early molecular steps that shape systemic physiological outcomes, which ultimately results in decreased propagation of overactive physiological responses and leads to predictable mechanistic adjustments that define the drug’s effect profile.

Dosage and Administration Information

How to Use Xusal: Official Administration Guidelines

Xusal (levocetirizine) is administered through the oral route, available as a 5 mg film-coated tablet or an oral solution. The fundamental principle of use is a once-daily schedule, typically administered in the evening.

Standard Dosing and Intake Conditions

The standard dose for adults and adolescents (age 12 years and older) is 5 mg once daily, representing the maximum recommended dose in a 24-hour period. A lower dose of 2.5 mg once daily may be used depending on symptom control. The medicine can be taken with or without food. The tablets are scored, which permits precise half-tablet (2.5 mg) dosing when necessary.

Population-Specific Use

Dosing regimens require modification for patients with reduced kidney function, based on estimated creatinine clearance (CLCR), as outlined in regulatory documents.

CLCR (mL/min)	Recommended Dose (Adults/Adolescents)
CLCR 50–80	2.5 mg once daily
CLCR 30–50	2.5 mg once every other day

For children aged 6 to 11 years, the recommended dose is 2.5 mg once daily. Children aged 6 months to 5 years are typically administered the 1.25 mg dose via the oral solution. No dose adjustment is generally required for patients with isolated hepatic impairment.

Course Duration and Missed Doses

For intermittent conditions, treatment may be paused when symptoms clear and restarted upon their return. If a dose is missed, patients should not take more than one dose within a 24-hour window. These instructions define the standardized, label-based approach for using Xusal.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Xusal

The research evidence for Xusal has been primarily collected through Randomized Controlled Trials (RCTs), which are a fundamental study design for testing a medicine, alongside Systematic Reviews that synthesize the results of multiple studies. This evidence base is used to describe what studies observed in research settings and to identify areas where research remains uncertain.

Evidence for Use in Seasonal and Perennial Allergic Rhinitis

Research has explored the symptom patterns associated with Xusal over time in allergic rhinitis, primarily through short-term, placebo-controlled trials. These studies were used to investigate the use of Xusal during conditions involving periods of heightened symptoms, such as during peak allergy seasons. The outcomes studied were related to physical discomfort, with researchers routinely applying specific scoring systems to measure episodic or acute changes in common allergy complaints.

Findings describe patterns observed in the studies regarding how symptoms evolved in the observed populations, noting how participants experienced and reported changes in their daily functioning. However, long-term outcomes are not fully characterized by large-scale, controlled RCTs. Follow-up durations were typically limited to a few weeks, meaning data are still emerging regarding continuous use over many months or years.

Evidence for Use in Chronic Hives (Chronic Idiopathic Urticaria)

For chronic hives, which are conditions characterized by fluctuating or episodic manifestations of itchy welts, Xusal was evaluated in research exploring periods where symptoms become more noticeable. Studies explored outcomes related to physical discomfort by examining standardized measurements of the severity of the itching (pruritus) and the size and frequency of the wheals (hives/welts).

Findings indicate patterns observed in the studies related to key measures of disease activity. The research exploring short-term symptom changes often had follow-up durations that were limited, frequently lasting six weeks or less in pivotal trials. There is limited information for long-term outcomes regarding the sustained control of this condition over many months.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Xusal (FAQ)

Q: How quickly should I expect Xusal to start working for allergies?

A: Official information indicates that after taking a standard oral dose, the active ingredient in Xusal reaches its peak concentration in the bloodstream in approximately one hour (0.9 hours). This pharmacokinetic information provides a context for the drug's absorption time, though individual symptom relief may vary.

Q: How long does the effect of one dose of Xusal typically last?

A: The regulatory information indicates that the medicine has an elimination half-life—the time it takes for half the drug to be eliminated from the body—of approximately 8 to 9 hours. This half-life information supports the drug's approved schedule as a once-daily treatment.

Q: Is Xusal known to cause drowsiness or fatigue in most people?

A: Regulatory documents list somnolence (drowsiness) and fatigue as two of the most common adverse reactions reported in clinical trials. For instance, drowsiness was reported in 5–6% of adult patients taking the standard dose. While these are known possibilities, regulatory data indicates that they do not occur in most patients.

Q: Can Xusal cause dry mouth or dry eyes?

A: Official adverse reaction data shows that dry mouth is a common side effect, reported in 2% or more of subjects aged 12 and older during clinical trials. Dry eyes is not explicitly listed among the common or uncommon adverse reactions documented in the clinical trial summaries.

Q: Is Xusal ever prescribed for children, and if so, what are the guidelines?

A: Yes, Xusal is formally indicated for use in children for conditions like perennial allergic rhinitis and chronic idiopathic urticaria, with use specified for ages as young as 6 months. The medicine’s official labeling includes age-specific instructions for use in children, which require a healthcare provider’s guidance.

Q: Is it normal to feel a slight headache when starting Xusal?

A: Official product information lists headache as a common adverse reaction that was observed during clinical trials. While regulatory documents do not specify if this symptom is exclusive to when the medication is first started, headache is a commonly reported finding in the adverse reaction profiles.

Q: What is the average duration of treatment with Xusal for seasonal allergies?

A: For seasonal allergic rhinitis (intermittent), official guidance states that treatment should be based on the individual's needs. The medicine can be stopped once symptoms clear and then restarted if they return, rather than requiring continuous therapy for a set duration.

Q: What happens to the body if you suddenly stop taking Xusal after using it for months?

A: The official label includes post-marketing reports of pruritus (itching)—sometimes severe—after discontinuing levocetirizine use. This effect has generally been reported in cases where the medicine was taken long-term (for months or years).

Q: Are there restrictions on driving or operating machinery while on Xusal?

A: Official labeling advises caution regarding activities requiring full mental alertness and coordination, such as driving a motor vehicle or operating heavy machinery. This caution is based on the potential for the side effects of somnolence (drowsiness) and fatigue.

Q: How is Xusal metabolized by the body?

A: Regulatory documents on pharmacokinetics indicate that the active ingredient is only minimally metabolized (broken down) by the body, accounting for less than 14% of the dose. The majority of the dose—approximately 85%—is eliminated as the unchanged drug, primarily through the kidneys.

Q: Does Xusal contain any ingredients that might be a concern for people with specific allergies (e.g., dyes, lactose)?

A: The official regulatory documents list all active and inactive ingredients (excipients) in the product. For instance, the Xusal film-coated tablets contain lactose monohydrate, and the oral solution contains ingredients such as propylene glycol.

Q: Are there any common digestive side effects associated with Xusal?

A: The most common gastrointestinal effect documented in clinical trials is dry mouth. While abdominal pain is also listed, it is considered an uncommon adverse reaction, occurring in less than 1% of patients.

Q: Why is Xusal sometimes used for non-seasonal allergies?

A: The medicine is formally indicated by regulatory agencies for use in conditions that are not strictly seasonal. These include perennial allergic rhinitis, which causes symptoms year-round, and the treatment of chronic idiopathic urticaria (chronic hives).

Q: Can Xusal affect my sleep patterns?

A: The official warning sections indicate that Xusal can cause somnolence (drowsiness) and fatigue. These are central nervous system effects that may potentially impact a person's overall alertness and affect their normal sleep timing or patterns.

Q: Are there any research papers discussing the long-term safety profile of Xusal?

A: There is clinical experience summarized in regulatory documents concerning the use of levocetirizine for treatment periods of at least 6 months in chronic allergic rhinitis. Further long-term data also exists for its related compound, cetirizine.

Q: Can Xusal cause weight gain, which is a common concern with some older allergy medications?

A: Based on official summaries of clinical trial data, weight gain has been listed as a common side effect. The full list of potential effects is documented in the medicine’s official patient information leaflet or regulatory labeling.

Q: What are the typical non-allergic conditions, if any, for which Xusal might be used?

A: Xusal is indicated only for allergic rhinitis (seasonal and perennial) and for treating the uncomplicated skin manifestations of chronic idiopathic urticaria (hives). Its approved use is restricted to these conditions.

How should Xusal be stored and disposed of?

How to Store and Dispose of Xusal

This information details the storage and disposal requirements for Xusal (levocetirizine dihydrochloride) based on official regulatory labeling.

Requirement Area	Official Statement
Storage Temperature	Store at controlled room temperature (20 C to 25 C).
Packaging	Keep the medicine in its original container. Do not use after the expiry date (EXP).
Child Safety	Keep this medicine out of the sight and reach of children.
Disposal	Do not throw away any medicines via wastewater or household waste. Dispose of unused product according to local requirements.

Storage outside of the mandatory range (15 C to 30 C excursions permitted) may compromise stability. Proper disposal according to local guidelines is necessary to help protect the environment and is required for unused or expired medicine.

Xusal